Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Actavis Inc    

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Watson Says Received Favorable Ruling Over Generic Sanctura XR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/04/2012 | 12:19am CEST

Watson Pharmaceuticals Inc. (>> Watson Pharmaceuticals, Inc.) said it received a favorable court ruling over a patent dispute with Allergan Inc. (AGN) and its business partners regarding Watson's plans for a generic version of an overactive bladder medication.

Allergan and its partners in 2009 sued Watson and its business partners, alleging infringement of patents related to Allergan's Sanctura XR drug.

Watson said Tuesday a U.S. District Court in Delaware found several Sanctura XR patents invalid, benefiting Watson and allowing it to potentially move forward with its abbreviated new drug application for generic version of the drug, which is pending with the Food and Drug Administration.

An Allergan representative wasn't immediately available for comment.

Watson has seen strong sales of its generics as health-care companies and consumers try to reduce spending on health-related products and services. Watson is trying to expand its brand-name drug business, though it recently hit a regulatory setback with a proposed new drug to prevent premature births.

The company benefited from its introduction of authorized generic versions of Johnson & Johnson's (JNJ) Concerta treatment for attention-deficit/hyperactivity disorder in May, as well as Pfizer's (PFE) Lipitor cholesterol-lowering drug in November.

Watson in February said its fourth-quarter profit surged as the introduction of generic Lipitor and other products boosted sales.

Watson's shares closed Tuesday at $66.96 and were down 6 cents after hours. Allergan's shares closed at $95.27 and were off 10 cents after hours.

-By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108; [email protected]

Stocks mentioned in the article : Watson Pharmaceuticals, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACTAVIS INC
05/16 CARL ICAHN : Icahn takes new 19.8 million share stake in Conduent in first quart..
05/16 ALLERGAN PLC : ex-dividend day
05/13 High-profile Snap stakeholders revealed in filings
05/13 High-profile Snap stakeholders revealed in filings
05/09DJALLERGAN : Thin Is In as Allergan Dodges Generics Bullet -- Heard on the Street
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/03DJPerrigo Says Investigators Searched Its Offices in Generic-Drug Probe
02/24 ALLERGAN PLC : ex-dividend day
02/21 Collapse of Kraft-Unilever tie-up extends run of failed mega-deals
02/13 Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 billion
More news
Sector news : Pharmaceuticals - NEC
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- 2nd Updat..
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- Update
05/23DJALEXION PHARMACEUTICALS : Management Shakeup Continues as Four More Executives E..
More sector news : Pharmaceuticals - NEC
Advertisement
Financials ($)
Sales 2017 15 821 M
EBIT 2017 7 624 M
Net income 2017 -1 759 M
Debt 2017 17 074 M
Yield 2017 1,31%
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 5,76x
EV / Sales 2018 5,35x
Capitalization 74 112 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 273 $
Spread / Average Target 24%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACTAVIS INC73 730
JOHNSON & JOHNSON10.46%342 817
ROCHE HOLDING LTD.14.79%237 610
NOVARTIS AG6.28%213 719
PFIZER INC.-1.05%191 279
MERCK & CO., INC.9.65%175 160
More Results